OP-110: An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

OP-110: An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

OP-110: An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

Sponsor: Oncopeptides AB

Principal Investigator: Karen Sweiss, PhD

Leave a Reply